IL277354B2 - Methods and compounds for downregulating soluble CD28 receptor - Google Patents

Methods and compounds for downregulating soluble CD28 receptor

Info

Publication number
IL277354B2
IL277354B2 IL277354A IL27735420A IL277354B2 IL 277354 B2 IL277354 B2 IL 277354B2 IL 277354 A IL277354 A IL 277354A IL 27735420 A IL27735420 A IL 27735420A IL 277354 B2 IL277354 B2 IL 277354B2
Authority
IL
Israel
Prior art keywords
antibody
agent
seq
scd28
acid sequence
Prior art date
Application number
IL277354A
Other languages
English (en)
Hebrew (he)
Other versions
IL277354B1 (en
IL277354A (en
Inventor
Motti Hakim
Dror Alishekevitz
Ziv Dana Haves
Edna Meilin
Yair Sapir
Avidor Shulman
Tehila Ben-Moshe
Ilana Mandel
Original Assignee
Biond Biologics Ltd
Motti Hakim
Dror Alishekevitz
Ziv Dana Haves
Edna Meilin
Yair Sapir
Avidor Shulman
Ben Moshe Tehila
Ilana Mandel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biond Biologics Ltd, Motti Hakim, Dror Alishekevitz, Ziv Dana Haves, Edna Meilin, Yair Sapir, Avidor Shulman, Ben Moshe Tehila, Ilana Mandel filed Critical Biond Biologics Ltd
Publication of IL277354A publication Critical patent/IL277354A/en
Publication of IL277354B1 publication Critical patent/IL277354B1/en
Publication of IL277354B2 publication Critical patent/IL277354B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70521—CD28, CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL277354A 2018-03-15 2019-03-14 Methods and compounds for downregulating soluble CD28 receptor IL277354B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862643355P 2018-03-15 2018-03-15
US201862643334P 2018-03-15 2018-03-15
US201862774254P 2018-12-02 2018-12-02
PCT/IL2019/050292 WO2019175885A1 (en) 2018-03-15 2019-03-14 Methods and compositions for decreasing soluble immune receptor cd28

Publications (3)

Publication Number Publication Date
IL277354A IL277354A (en) 2020-11-30
IL277354B1 IL277354B1 (en) 2025-03-01
IL277354B2 true IL277354B2 (en) 2025-07-01

Family

ID=66182618

Family Applications (1)

Application Number Title Priority Date Filing Date
IL277354A IL277354B2 (en) 2018-03-15 2019-03-14 Methods and compounds for downregulating soluble CD28 receptor

Country Status (10)

Country Link
US (2) US12139534B2 (enExample)
EP (1) EP3765518A1 (enExample)
JP (1) JP7691823B2 (enExample)
KR (1) KR20200131260A (enExample)
CN (2) CN112074539B (enExample)
AU (1) AU2019234183B2 (enExample)
BR (1) BR112020018279A2 (enExample)
CA (1) CA3093647A1 (enExample)
IL (1) IL277354B2 (enExample)
WO (1) WO2019175885A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019234183B2 (en) 2018-03-15 2025-12-18 Biond Biologics Ltd. Methods and compositions for decreasing soluble immune receptor CD28
CN113692286A (zh) * 2019-03-14 2021-11-23 比昂生物制剂公司 一种用于免疫抑制的方法
EP3938397A1 (en) 2019-03-14 2022-01-19 Biond Biologics Ltd. Small shedding blocking agents
US12612459B2 (en) * 2019-12-02 2026-04-28 Biond Biologics Ltd. Methods of identifying agents that block MCD28 cleavage by MMPS
CN114902046A (zh) * 2019-12-02 2022-08-12 比昂生物制剂公司 免疫疗法期间可溶性cd28水平
US20230221325A1 (en) * 2019-12-02 2023-07-13 Biond Biologics Ltd. Soluble cd28 levels after immunotherapy
KR20220152555A (ko) * 2020-03-12 2022-11-16 비온드 바이오로직스 엘티디 증가된 안정성을 가진 쉐딩 차단제
EP4399229A2 (en) 2021-09-06 2024-07-17 Biond Biologics Ltd. Cd28 shedding blocking agents
JP2025510948A (ja) * 2022-03-31 2025-04-15 サナ バイオテクノロジー，インコーポレイテッド Ｃｄ４特異的抗体構築物及び組成物ならびにその使用
TW202545991A (zh) * 2024-01-12 2025-12-01 大陸商信達生物製藥（蘇州）有限公司 抗ｃｄ２８抗體及其用途
WO2025215647A1 (en) 2024-04-11 2025-10-16 Biond Biologics Ltd. Combination cancer treatment with staggered dosing

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1378520A1 (en) * 2001-04-11 2004-01-07 Institute of Genetics, Chinese Academy of Sciences Cyclic single strand trispecific antibody
US20080038273A1 (en) * 2000-12-26 2008-02-14 Institut National De La Sante Et De La Recherche Medicale (Inserm) Anti-Cd28 Antibody

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
IL148993A0 (en) 2002-04-04 2002-11-10 Yissum Res Dev Co Broad-spectrum in-vivo effective superantigen toxin antagonists based on the interaction between cd28 and the superantigen and uses thereof
EP1622569B1 (en) * 2003-04-24 2015-12-02 Incyte Corporation Aza spiro alkane derivatives as inhibitors of metallproteases
GB0400440D0 (en) 2004-01-09 2004-02-11 Isis Innovation Receptor modulators
CN100509849C (zh) 2005-04-07 2009-07-08 苏州大学 可溶性人cd28分子检测试剂盒及其应用
MX2011000501A (es) 2008-07-18 2011-05-23 Squibb Bristol Myers Co Composiciones monovalentes para union a cd28 y metodos de uso.
AU2019234183B2 (en) 2018-03-15 2025-12-18 Biond Biologics Ltd. Methods and compositions for decreasing soluble immune receptor CD28

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080038273A1 (en) * 2000-12-26 2008-02-14 Institut National De La Sante Et De La Recherche Medicale (Inserm) Anti-Cd28 Antibody
EP1378520A1 (en) * 2001-04-11 2004-01-07 Institute of Genetics, Chinese Academy of Sciences Cyclic single strand trispecific antibody

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DANIEL ET AL,, COSTIMULATION WITH AGONISTIC ANTI-CD28 ANTIBODIES PREVENTS T CELL APOPTOSIS AND IS REQUIRED FOR EFFICIENT IMMUNOTHERAPY WITH CD3X19 BISPECIFIC ANTIBODIES IN B CELL LYMPHOMA, 1 June 1997 (1997-06-01) *
EGAN E MURRAY ET AL,, CD28-MEDIATED PRO-SURVIVAL SIGNALING INDUCES CHEMOTHERAPEUTIC RESISTANCE IN MULTIPLE MYELOMA, 29 April 2014 (2014-04-29) *
HUANG YANCHAO ET AL,, TARGETING THE SHEDDASE ACTIVITY OF ADAM17 BY AN ANTI-ADAM17 ANTIBODY D1(A12) INHIBITS HEAD AND NECK SQUAMOUS CELL CARCINOMA CELL PROLIFERATION AND MOTILITY VIA BLOCKAGE OF BRADYKININ INDUCED HERS TRANSACTIVATION., 31 December 2014 (2014-12-31) *
ISITMANGIL,, ASSOCIATION OF CTLA4 AND CD28 GENE VARIANTS AND CIRCULATING LEVELS OF THEIR PROTEINS IN PATIENTS WITH BREAST CANCER, 1 January 2016 (2016-01-01) *

Also Published As

Publication number Publication date
WO2019175885A1 (en) 2019-09-19
AU2019234183B2 (en) 2025-12-18
CA3093647A1 (en) 2019-09-19
EP3765518A1 (en) 2021-01-20
US20240309094A1 (en) 2024-09-19
CN112074539B (zh) 2025-01-24
JP7691823B2 (ja) 2025-06-12
US20210047411A1 (en) 2021-02-18
JP2021517152A (ja) 2021-07-15
IL277354B1 (en) 2025-03-01
CN119775419A (zh) 2025-04-08
US12139534B2 (en) 2024-11-12
KR20200131260A (ko) 2020-11-23
IL277354A (en) 2020-11-30
BR112020018279A2 (pt) 2020-12-29
AU2019234183A1 (en) 2020-10-01
CN112074539A (zh) 2020-12-11

Similar Documents

Publication Publication Date Title
US20240309094A1 (en) Methods and compositions for decreasing soluble immune receptor cd28
US20260139054A1 (en) Small shedding blocking agents
IL250848B (en) Cancer cell-specific antibody, anti-cancer drug and cancer diagnosis method
IL267340B2 (en) Anti-pcna monoclonal antibodies and use thereof
IL320488A (en) Anti-cd16a antibody and application thereof
JP7860896B2 (ja) Ｍｍｐ抑制の使用
IL316523A (en) Anti-ilt3 antibodies and use thereof
IL296372A (en) Highly stable anti-shedding materials
IL311275A (en) Materials that block and/or screen c. 28 is enough
HK40064257A (en) Small shedding blocking agents